Myriad loses some private insurance coverage for BRCA tests; Atossa Genetics adopts M&A poison pill;

> Horizon Blue Cross Blue Shield of New Jersey and Amerigroup have separately told providers in their networks to stop using Myriad Genetics ($MYGN) for BRCA diagnostic testing. Story (reg. req.)

> Atossa Genetics ($ATOS), under fire for allegedly making misleading claims about its breast cancer test, has adopted a poison pill to fend off unwanted suitors. Story

> BioTime ($BTX) subsidiary OncoCyte has sealed a licensing deal with Weill Cornell Medical College to accelerate lung cancer diagnostic product development. Release

> A new esophageal cancer biomarker is showing some potential in helping to screen for the disease and early scarring that can lead to it. Story

> PerkinElmer ($PKI) said it will distribute Sebia's newborn blood screening test globally. Item (req. req.)

> Researchers have identified a new biomarker for oxidative stress generated during exercise, a physical response thought to be linked to some cancers, heart disease, Alzheimer's disease and other illnesses. Item

Suggested Articles

J&J’s Ethicon unit received an FDA clearance for its Vistaseal applicators that spray a biologic sealant from Grifols to help stem surgical bleeding.

Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.